SCHEMBL24543289

SCHEMBL24543289

CC(C)Oc1ccc(-c2ccc(NC(=O)C(C)(C)Oc3ccc(F)cc3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ GLA P06280 1/20 0.49
▸ ADORA2A P29274 1/20 0.48
▸ ADORA2B P29275 1/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ LMNA P02545 5/20 0.46
▸ PPARA Q07869 2/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ PTPN1 P18031 1/20 0.44
▸ TP53 P04637 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ CNR1 P21554 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24542732 0.87 EPHX2 (0.56) ALDH1A1SMN1; SMN2ADORA2AADORA2BCYP1A2
SCHEMBL24542774 0.87 CYP1A2 (0.43) ALDH1A1SMN1; SMN2ADORA2AADORA2BCYP1A2
SCHEMBL24542730 0.86 PDK1 (0.55) ALDH1A1SMN1; SMN2ADORA2AADORA2BCYP1A2
SCHEMBL24543220 0.85 PPARA (0.49) ALDH1A1SMN1; SMN2ADORA2AADORA2BCYP1A2
SCHEMBL24543203 0.84 CNR1 (0.53) ALDH1A1ADORA2AADORA2BCYP1A2CYP3A4
SCHEMBL24542754 0.84 ADORA2A (0.46) ALDH1A1SMN1; SMN2ADORA2AADORA2BCYP1A2
SCHEMBL24542766 0.84 TRPV1 (0.54) SMN1; SMN2ADORA2AADORA2BCYP1A2CYP3A4
SCHEMBL24543109 0.82 PPARA (0.54) ALDH1A1ADORA2AADORA2BCYP1A2CYP3A4
SCHEMBL24542744 0.81 CYP1A2 (0.53) ALDH1A1SMN1; SMN2ADORA2AADORA2BCYP1A2
SCHEMBL24542738 0.80 TRPV1 (0.55) ALDH1A1SMN1; SMN2ADORA2AADORA2BCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4263492-B1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARM INC (US) 2025-04-09 — — EP disclosed
US-20240132450-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 ACADIA PHARMACEUTICALS INC. 2024-04-25 — — US disclosed
WO-2022129933-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 Pandeia Therapeutics Limited (GB) 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132450-A1 MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 GPR88, GPR65, GPR68 ALDH1A1 2127/4885SMN1; SMN2 2024/4885GLA 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback